BDZ-P7

BDZ-P7 inhibits AMPA receptor GluA2, GluA1/2, GluA2/3, and GluA1 subunit with IC50s of 3.03 μM, 3.14 μM, 3.19 μM, 3.2 μM. BDZ-P7 has neuroprotective effect and reinstates locomotor abilities in a mouse model of Parkinson’s disease[1].

Product Specifications

UNSPSC

12352005

Target

IGluR

Type

Reference compound

Related Pathways

Membrane Transporter/Ion Channel; Neuronal Signaling

Applications

Neuroscience-Neurodegeneration

Field of Research

Neurological Disease

Assay Protocol

https://www.medchemexpress.com/bdz-p7.html

Smiles

CC(C(NC1=C(OC)C=C(Cl)C(OC)=C1)=O)CC2=CC(OCO3)=C3C=C2

Molecular Formula

C19H20ClNO5

Molecular Weight

377.82

References & Citations

[1]Hawash M, et al. Evaluating the Neuroprotective Potential of Novel Benzodioxole Derivatives in Parkinson's Disease via AMPA Receptor Modulation. ACS Chem Neurosci. 2024 May 15.